Growing evidence suggests that blood eosinophil count is associated with patient responsiveness to inhaled corticosteroids (ICS). We performed post hoc predictive modeling on data from the FORWARD study and two replicate studies by Dransfield, to evaluate the relationships between baseline eosinophil count and the effect of ICS on exacerbations and lung function in patients with COPD.
The studies assessed ICS/long-acting β2 agonist (LABA) combin...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- Dove Press Publisher's website
- International Journal of Chronic Obstructive Pulmonary Disease Journal website
- Publication date:
- Acceptance date:
1176-9106 and 1178-2005
- Pubs id:
- Local pid:
- Copyright holder:
- Siddiqui et al.
- Copyright date:
- © 2018 Siddiqui et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record